Skip to main content

Compounding Drugs for Intrathecal Use

  • Chapter
  • First Online:
  • 1623 Accesses

Abstract

Choosing the correct intrathecal drug medication or combination of medications has historically been an art of trial and error with some historical perspective. More recently, compounding pharmacies have had increased national scrutiny in safety practices. In this chapter, we will review options for intrathecal drug delivery management, as well as explore guides for compounding sterile preparations, and provide the reader with stability data on common compounded formulations of intrathecal drugs.

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Stearns L, Boortz-Marx R, Du Pen S, et al. Intrathecal drug delivery for the management of cancer pain: a multidisciplinary consensus of best clinical practices. J Support Oncol. 2005;3:399–408.

    CAS  PubMed  Google Scholar 

  2. Weiss N, North RB, Ohara S, et al. Attenuation of cerebellar tremor with implantation of an intrathecal baclofen pump: the role of gamma-aminobutyric acidergic pathways. Case report. J Neurosurg. 2003;99:768–71.

    Article  Google Scholar 

  3. Ho KM, Ismail H. Use of intrathecal midazolam to improve perioperative analgesia: a meta-analysis. Anaesth Intensive Care. 2008;36:365–73.

    CAS  PubMed  Google Scholar 

  4. Yaksh TL, Hassenbusch S, Burchiel K, et al. Inflammatory masses associated with intrathecal drug infusion: a review of preclinical evidence and human data. Pain Med. 2002;3:300–12.

    Article  Google Scholar 

  5. Siddall PJ, Gray M, Rutkowski S, et al. Intrathecal morphine and clonidine in the management of spinal cord injury pain: a case report. Pain. 1994;59:147–8.

    Article  CAS  Google Scholar 

  6. Convention USP. 2009; Chapter 797, United States Pharmacopeia/National Formulary 1st ed. US Pharmacopeia; 4139.

    Google Scholar 

  7. Kastango E. The ASHP discussion guide for compounding sterile preparations: summary and implementation of USP Chapter 797 2004. ASHP Publishing.

    Google Scholar 

  8. Outterson K. Regulating compounding pharmacies after NECC. N Engl J Med. 2012;367:1986–72.

    Google Scholar 

  9. Yaksh TL, Horais KA, Tozier NA, et al. Chronically infused intrathecal morphine in dogs. Anesthesiology. 2003;99:174–87.

    Article  CAS  Google Scholar 

  10. Deer T, Krames ES, Hassenbusch SJ, et al. Polyanalgesic Consensus Conference 2007: recommendations for the management of pain by intrathecal (Intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation. 2007;10:300–28.

    Article  Google Scholar 

  11. Hildebrand KR, Elsberry DE, Anderson VC. Stability and compatibility of hydromorphone hydrochloride in an implantable infusion system. J Pain Symptom Manag. 2001;22:1042–7.

    Article  CAS  Google Scholar 

  12. Deer TR, Serafini M, Buchser E, et al. Intrathecal bupivacaine for chronic pain: a review of current knowledge. Neuromodulation. 2002;5:196–207.

    Article  Google Scholar 

  13. Trissel L, editor. Trissel’s stability of compounded formulations. 4nd ed. Washington, DC: APHA Publications; 2009.

    Google Scholar 

  14. O’Neil M, Smith A, Heckelman P, et al., editors. Merck index. 13th ed. New York: Wiley; 2001.

    Google Scholar 

  15. Yeager MP, Colacchio TA, Yu CT, et al. Morphine inhibits spontaneous and cytokine-enhanced natural killer cell cytotoxicity in volunteers. Anesthesiology. 1995;83(3):500–8.

    Article  CAS  Google Scholar 

  16. Deer TR, Raso LJ, Coffey RJ, et al. Intrathecal baclofen and catheter tip inflammatory mass lesions (granulomas): a reevaluation of case reports and imaging findings in light of experimental, clinicopathological, and radiological evidence. Pain Med. 2008;9:391–5.

    Article  CAS  Google Scholar 

  17. Gradert TL, Baze WB, Satterfield WC, et al. Safety of chronic intrathecal morphine infusion in a sheep model. Anesthesiology. 2003;99:188–98.

    Article  CAS  Google Scholar 

  18. Coffey RJ, Burchiel K. Inflammatory mass lesions associated with intrathecal drug infusion catheters: report and observations on 41 patients. Neurosurgery. 2002;50:78–86. discussion 86-77.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Shah, S. (2019). Compounding Drugs for Intrathecal Use. In: Gulati, A., Puttanniah, V., Bruel, B., Rosenberg, W., Hung, J. (eds) Essentials of Interventional Cancer Pain Management. Springer, Cham. https://doi.org/10.1007/978-3-319-99684-4_33

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-99684-4_33

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-99682-0

  • Online ISBN: 978-3-319-99684-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics